SecBot SecBot
8-K ·Filed Aug 10, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago SEC0001193125-26-342328
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

SEP-479 SAD/MAD data in Q1 2027 is the next major binary catalyst. The SEP-631 strategic pivot from a Phase 2b CSU study to signal-finding studies suggests a more cautious, capital-efficient approach, watch for clarity on study design and indications. The Novo Nordisk collaboration provides a steady revenue stream, but the stock remains a pipeline story. Cash runway into 2029 removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

SEPN drug pipeline →

SEP-479

● Neutral Named in this 8-K
Impact
Phase
Phase 1
Time to market
If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.

Price Chart

Loading chart...

Executive Summary

Septerna reported Q2 2026 financial results with a net loss of $13.0M, narrower than the $24.8M loss in Q2 2025. Revenue from the Novo Nordisk collaboration was $26.7M, and the company ended the quarter with $516.5M in cash, sufficient to fund operations into 2029. Key pipeline updates include the ongoing Phase 1 trial for SEP-479 (PTH1R agonist) with SAD/MAD data expected in Q1 2027, and a strategic shift for SEP-631 away from a Phase 2b CSU study toward capital-efficient signal-finding studies in mast cell-driven diseases.

Key Financial Metrics

Revenue
$26.7M

Key Facts

  • Net loss of $13.0M for Q2 2026 vs $24.8M for Q2 2025; revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex in Q2 2025.
  • Cash position of $516.5M as of June 30, 2026, expected to fund operations at least into 2029.
  • Phase 1 trial for SEP-479 (PTH1R agonist) ongoing; elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
  • SEP-631 strategic shift: company evaluating capital-efficient signal-finding studies in mast cell-driven diseases instead of the previously planned Phase 2b in CSU.
  • TSHR NAM program progressing toward development candidate selection; Novo Nordisk collaboration advancing.

Financial Impact

No material financial impact; Q2 net loss $13.0M, revenue $26.7M, cash burn rate consistent with prior quarter.

revenuenetLosscashPosition

Risk Factors

  • SEP-479 Phase 1 data delay or negative safety/efficacy findings in Q1 2027.
  • SEP-631 development uncertainty due to strategic reprioritization away from Phase 2b CSU.
  • High R&D spend ($35.1M in Q2) may accelerate cash burn if pipeline timelines slip.
  • Early-stage pipeline, no approved products; all value tied to clinical execution.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-342328
Document: sepn-20260810.htm0001193125-26-342328
Document: 0001193125-26-342328-index-headers.html0001193125-26-342328
Document: 0001193125-26-342328-index.html0001193125-26-342328
Document: 0001193125-26-342328.txt0001193125-26-342328
8-K Data (Synthetic)0001193125-26-342328

US Market Status

Market Closed · Opens Wed (12h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026